The Swedish BioFINDER Study
The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.
News articles
New blood biomarker reduces the risk of misdiagnosing Alzheimer’s disease.
The new blood tests for diagnosing Alzheimer’s disease are providing increasingly better opportunities for early diagnosis, but one challenge...
Read more...Blood Tests: Not Just for the Impaired?
In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease...
Read more...
Recent key publications
- 23 March, 2026
Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer’s disease: a prospective cohort study
- 6 October, 2025
Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers
- 27 September, 2025
Alzheimer’s disease outlook: controversies and future directions
- 16 September, 2025
Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers
X posts
New publication alert!
Are patients seen in primary care eligible for amyloid-targeting therapies (ATT) for treatment of Alzheimer’s disease? 🧠We evaluated ATT eligibility among patients with cognitive symptoms in primary care in southern Sweden.
Eligibility for amyloid targeting therapies among primary care patients with cognitive symptoms
Alzheimer's Research & Therapy - Alzheimer’s disease (AD) is the most common cause of dementia and a growing hea...
link.springer.com
This study was led by Beata Borgström Bolmsjö. A big thanks to all collaborators and co-authors: @DaniellevWe @SuzanneESchind1 @LECollij @ErikRubenSmith @NiklasMattsson4 @EStomrud @SebastianPalmqv and all not on X.
New publication out in Brain! 📢We developed a data-driven multimodal biomarker framework to characterize a memory clinic cohort based on the presence, extent, and sequence of common pathologies. This framework may support diagnosis and trial selection.
🔗
Biological classification of memory clinic patients
Mastenbroek et al. present a biological framework developed to categorize individuals in a memory clinic cohort based ...
academic.oup.com
The study was led by @SEMastenbroek, a huge thank you to all co-authors: @LECollij, @teanijarv, @jorittmo, @YoungAlexL, @ErikRubenSmith, @NicolaSpotorno, @SebastianPalmqv, @NiklasMattsson4, @_JakeVogel_, @FBarkhof, @RikOssenkoppele and all not on X.
New publication out in Brain! 📢
We found that reference proteins Aβ40 and np-tau consistently helped already high-performing fluid biomarkers (e.g., MTBR-tau243 and p-tau variants) to more reliably represent brain Aβ and tau pathology measured by PET.
🔗
Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers
Karlsson et al. show that normalizing Alzheimer’s disease cerebrospinal fluid and plasma biomarkers to reference prote...
academic.oup.com
The study was led by @karlssonlinda1, a huge thank you to @KantaHorie @JosephTherr @SuzanneESchind1 @_JakeVogel_ @astromkalle @BrianGordon81 @cyrusraji @tlsmit1 @SebastianPalmqv @EStomrud @gesalbla @pedrorosaneto @RandallBateman3 @NiklasMattsson4 🔗
Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers
Karlsson et al. show that normalizing Alzheimer’s disease cerebrospinal fluid and plasma biomarkers to reference prote...
academic.oup.com